Payment overview · 2025
General Payments
$70.41
7 reported records · 4 companies
Healthcare provider profile · identity verified
Joseph Thomas, DO
Allopathic & Osteopathic Physicians|Family Medicine · WEATHERFORD, TX · NPI 1033649611
Verified facts
What the public records show
CMS Open Payments records show Joseph Thomas, DO received $70.41 in general payments during 2025 across 7 reported records.
Phathom Pharmaceuticals, Inc. accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.32 | 38.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.18 | 30.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.77 | 23.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $5.14 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $70.41 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.32 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $5.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 375 | 138 |
| Montelukast Sodium | Montelukast Sodium | 311 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 265 | 90 |
| Gabapentin | Gabapentin | 245 | 82 |
| Losartan Potassium | Losartan Potassium | 234 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 82 |
| Metformin Hcl | Metformin Hcl | 189 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 188 | 56 |
| Lisinopril | Lisinopril | 183 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 68 |
| Omeprazole | Omeprazole | 160 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 57 |
| Celecoxib | Celecoxib | 142 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 45 |
| Ezetimibe | Ezetimibe | 114 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 46 |
| Simvastatin | Simvastatin | 104 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 33 |
| Trazodone Hcl | Trazodone Hcl | 71 | 23 |
| Furosemide | Furosemide | 70 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 21 |
| Alprazolam | Alprazolam | 67 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 21 |
| Carvedilol | Carvedilol | 63 | 19 |
| Allopurinol | Allopurinol | 62 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 23 |
| Glimepiride | Glimepiride | 61 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 20 |
| Sertraline Hcl | Sertraline Hcl | 56 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 20 |
| Meloxicam | Meloxicam | 54 | 25 |
| Bupropion Xl | Bupropion Hcl | 53 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 31 |
| Prednisone | Prednisone | 49 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 45 |
| Alendronate Sodium | Alendronate Sodium | 46 | 17 |
| Meclizine Hcl | Meclizine Hcl | 46 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Eliquis | Apixaban | 45 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 12 |
| Potassium Chloride | Potassium Chloride | 44 | 23 |
| Cefdinir | Cefdinir | 43 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 16 |
| Spironolactone | Spironolactone | 40 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 35 |
| Atenolol | Atenolol | 37 | 11 |
| Ondansetron Odt | Ondansetron | 37 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 36 | 31 |
| Finasteride | Finasteride | 36 | 11 |
| Buspirone Hcl | Buspirone Hcl | 35 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 16 |
| Memantine Hcl | Memantine Hcl | 34 | 13 |
| Clonazepam | Clonazepam | 33 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 16 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 16 |
| Methocarbamol | Methocarbamol | 26 | 15 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | 13 |
| Estradiol | Estradiol | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 20 |
| Glipizide | Glipizide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | 11 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Nystatin | Nystatin | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Famotidine | Famotidine | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $70.41 · 7 records | Phathom Pharmaceuticals, Inc. | ELIQUIS, NEXPLANON, NURTEC ODT, TRELEGY ELLIPTA, VOQUEZNA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error